These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
109 related articles for article (PubMed ID: 24044648)
1. Nanoparticles laden in situ gel of levofloxacin for enhanced ocular retention. Gupta H; Aqil M; Khar RK; Ali A; Bhatnagar A; Mittal G Drug Deliv; 2013; 20(7):306-9. PubMed ID: 24044648 [TBL] [Abstract][Full Text] [Related]
2. Biodegradable levofloxacin nanoparticles for sustained ocular drug delivery. Gupta H; Aqil M; Khar RK; Ali A; Bhatnagar A; Mittal G J Drug Target; 2011 Jul; 19(6):409-17. PubMed ID: 20678034 [TBL] [Abstract][Full Text] [Related]
3. Nanoparticles laden in situ gel for sustained ocular drug delivery. Gupta H; Aqil M; Khar RK; Ali A; Bhatnagar A; Mittal G J Pharm Bioallied Sci; 2013 Apr; 5(2):162-5. PubMed ID: 23833523 [TBL] [Abstract][Full Text] [Related]
4. Sparfloxacin-loaded PLGA nanoparticles for sustained ocular drug delivery. Gupta H; Aqil M; Khar RK; Ali A; Bhatnagar A; Mittal G Nanomedicine; 2010 Apr; 6(2):324-33. PubMed ID: 19857606 [TBL] [Abstract][Full Text] [Related]
6. Formulation and optimization of levofloxacin loaded chitosan nanoparticle for ocular delivery: In-vitro characterization, ocular tolerance and antibacterial activity. Ameeduzzafar ; Imam SS; Abbas Bukhari SN; Ahmad J; Ali A Int J Biol Macromol; 2018 Mar; 108():650-659. PubMed ID: 29199125 [TBL] [Abstract][Full Text] [Related]
7. Chitosan coated PLGA nanoparticles amplify the ocular hypotensive effect of forskolin: Statistical design, characterization and in vivo studies. Khan N; Ameeduzzafar ; Khanna K; Bhatnagar A; Ahmad FJ; Ali A Int J Biol Macromol; 2018 Sep; 116():648-663. PubMed ID: 29723623 [TBL] [Abstract][Full Text] [Related]
8. A poloxamer/chitosan in situ forming gel with prolonged retention time for ocular delivery. Gratieri T; Gelfuso GM; Rocha EM; Sarmento VH; de Freitas O; Lopez RF Eur J Pharm Biopharm; 2010 Jun; 75(2):186-93. PubMed ID: 20188828 [TBL] [Abstract][Full Text] [Related]
9. Vitamin E TPGS-emulsified poly(lactic-co-glycolic acid) nanoparticles for cardiovascular restenosis treatment. Feng SS; Zeng W; Teng Lim Y; Zhao L; Yin Win K; Oakley R; Hin Teoh S; Hang Lee RC; Pan S Nanomedicine (Lond); 2007 Jun; 2(3):333-44. PubMed ID: 17716178 [TBL] [Abstract][Full Text] [Related]
10. Development of loteprednol etabonate-loaded cationic nanoemulsified in-situ ophthalmic gel for sustained delivery and enhanced ocular bioavailability. Patel N; Nakrani H; Raval M; Sheth N Drug Deliv; 2016 Nov; 23(9):3712-3723. PubMed ID: 27689408 [TBL] [Abstract][Full Text] [Related]
11. Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. Gaspar MC; Grégoire N; Sousa JJ; Pais AA; Lamarche I; Gobin P; Olivier JC; Marchand S; Couet W Eur J Pharm Sci; 2016 Oct; 93():184-91. PubMed ID: 27531420 [TBL] [Abstract][Full Text] [Related]
12. Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration. Yang H; Tyagi P; Kadam RS; Holden CA; Kompella UB ACS Nano; 2012 Sep; 6(9):7595-606. PubMed ID: 22876910 [TBL] [Abstract][Full Text] [Related]
13. Ion- and pH-activated novel in-situ gel system for sustained ocular drug delivery. Gupta H; Velpandian T; Jain S J Drug Target; 2010 Aug; 18(7):499-505. PubMed ID: 20055752 [TBL] [Abstract][Full Text] [Related]
14. Preparation of levofloxacin loaded Jain P; Jaiswal CP; Mirza MA; Anwer MK; Iqbal Z Drug Dev Ind Pharm; 2020 Jan; 46(1):50-56. PubMed ID: 31818154 [TBL] [Abstract][Full Text] [Related]
15. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel. Feng SS; Mei L; Anitha P; Gan CW; Zhou W Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012 [TBL] [Abstract][Full Text] [Related]
16. Promising ion-sensitive in situ ocular nanoemulsion gels of terbinafine hydrochloride: design, in vitro characterization and in vivo estimation of the ocular irritation and drug pharmacokinetics in the aqueous humor of rabbits. Tayel SA; El-Nabarawi MA; Tadros MI; Abd-Elsalam WH Int J Pharm; 2013 Feb; 443(1-2):293-305. PubMed ID: 23333217 [TBL] [Abstract][Full Text] [Related]
17. Polymeric nanoparticles augment the ocular hypotensive effect of melatonin in rabbits. Musumeci T; Bucolo C; Carbone C; Pignatello R; Drago F; Puglisi G Int J Pharm; 2013 Jan; 440(2):135-40. PubMed ID: 23078856 [TBL] [Abstract][Full Text] [Related]
18. An alternative in situ gel-formulation of levofloxacin eye drops for prolong ocular retention. Gupta H; Aqil M; Khar RK; Ali A; Bhatnagar A; Mittal G J Pharm Bioallied Sci; 2015; 7(1):9-14. PubMed ID: 25709330 [TBL] [Abstract][Full Text] [Related]
19. One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis. Ohashi K; Kabasawa T; Ozeki T; Okada H J Control Release; 2009 Apr; 135(1):19-24. PubMed ID: 19121349 [TBL] [Abstract][Full Text] [Related]
20. Biodegradable in situ gelling system for subcutaneous administration of ellagic acid and ellagic acid loaded nanoparticles: evaluation of their antioxidant potential against cyclosporine induced nephrotoxicity in rats. Sharma G; Italia JL; Sonaje K; Tikoo K; Ravi Kumar MN J Control Release; 2007 Mar; 118(1):27-37. PubMed ID: 17258836 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]